[go: up one dir, main page]

EE200200506A - 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid - Google Patents

5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid

Info

Publication number
EE200200506A
EE200200506A EEP200200506A EEP200200506A EE200200506A EE 200200506 A EE200200506 A EE 200200506A EE P200200506 A EEP200200506 A EE P200200506A EE P200200506 A EEP200200506 A EE P200200506A EE 200200506 A EE200200506 A EE 200200506A
Authority
EE
Estonia
Prior art keywords
alkylpyrido
pyrimidines
tyrosine kinase
kinase inhibitors
inhibitors
Prior art date
Application number
EEP200200506A
Other languages
English (en)
Inventor
Laurence Toogood Peter
John Booth Richard
Myra Dobrusin Ellen
Norman Vanderwel Scott
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200506A publication Critical patent/EE200200506A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200506A 2000-03-06 2001-01-29 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid EE200200506A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EE200200506A true EE200200506A (et) 2004-02-16

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200506A EE200200506A (et) 2000-03-06 2001-01-29 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid

Country Status (36)

Country Link
EP (1) EP1268476A1 (et)
JP (1) JP2003528101A (et)
KR (1) KR20020075805A (et)
CN (1) CN1422268A (et)
AP (1) AP2002002643A0 (et)
AR (1) AR034119A1 (et)
AU (1) AU2001233028A1 (et)
BG (1) BG107161A (et)
BR (1) BR0109056A (et)
CA (1) CA2401368A1 (et)
CO (1) CO5280200A1 (et)
CR (1) CR6736A (et)
CZ (1) CZ20022929A3 (et)
DZ (1) DZ3308A1 (et)
EA (1) EA200200802A1 (et)
EE (1) EE200200506A (et)
GT (1) GT200100037A (et)
HN (1) HN2001000040A (et)
HR (1) HRP20020798A2 (et)
HU (1) HUP0300136A2 (et)
IL (1) IL151480A0 (et)
IS (1) IS6524A (et)
MA (1) MA26881A1 (et)
MX (1) MXPA02008535A (et)
NO (1) NO20024235L (et)
NZ (1) NZ520962A (et)
OA (1) OA12227A (et)
PA (1) PA8513201A1 (et)
PE (1) PE20011177A1 (et)
PL (1) PL358271A1 (et)
SK (1) SK12472002A3 (et)
SV (1) SV2001000338A (et)
TN (1) TNSN01036A1 (et)
WO (1) WO2001070741A1 (et)
YU (1) YU66502A (et)
ZA (1) ZA200207110B (et)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002059083A2 (en) 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
CA2438294C (en) 2001-02-26 2008-10-21 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP4603268B2 (ja) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004033446A1 (en) 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
ATE433967T1 (de) * 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
NZ544609A (en) * 2003-07-11 2008-07-31 Warner Lambert Co Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
JP5010917B2 (ja) * 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
SG160438A1 (en) 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP5480503B2 (ja) * 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PL2074122T3 (pl) 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
JP2010506902A (ja) * 2006-10-16 2010-03-04 ジーピーシー・バイオテック・インコーポレーテッド ピリド［２，３−ｄ］ピリミジン類およびキナーゼ阻害剤としてのそれらの使用
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
SI2168966T1 (sl) 2007-06-15 2017-03-31 Msd K.K. Derivat biciklo anilina
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ATE531372T1 (de) * 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2012004157A (es) * 2009-10-09 2012-08-03 Afraxis Inc 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
KR102027598B1 (ko) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
JP6631616B2 (ja) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
PE20190475A1 (es) 2016-08-15 2019-04-04 Pfizer Inhibidores de cdk2/4/6
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
EP3752491A4 (en) 2018-02-15 2021-12-01 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
CN113166148B (zh) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
WO2022188755A1 (zh) * 2021-03-08 2022-09-15 暨南大学 吡啶并嘧啶类化合物及其应用
KR20240021239A (ko) * 2021-06-09 2024-02-16 티와이케이 메디슨즈, 인코포레이티드 Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
JP2025531320A (ja) * 2022-09-16 2025-09-19 イースト チャイナ ノーマル ユニバーシティ Ｒｓｋ阻害剤としてのピリドノピリミジン誘導体及びその応用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
BR9807305A (pt) * 1997-02-05 2000-05-02 Warner Lambert Co Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘

Also Published As

Publication number Publication date
BR0109056A (pt) 2003-06-03
CA2401368A1 (en) 2001-09-27
PE20011177A1 (es) 2001-11-23
DZ3308A1 (fr) 2001-09-27
NZ520962A (en) 2003-09-26
NO20024235L (no) 2002-11-05
CZ20022929A3 (cs) 2003-02-12
EP1268476A1 (en) 2003-01-02
BG107161A (en) 2003-06-30
WO2001070741A1 (en) 2001-09-27
HN2001000040A (es) 2001-09-06
SK12472002A3 (sk) 2003-04-01
AU2001233028A1 (en) 2001-10-03
EA200200802A1 (ru) 2003-02-27
OA12227A (en) 2004-03-18
GT200100037A (es) 2002-03-04
CN1422268A (zh) 2003-06-04
MA26881A1 (fr) 2004-12-20
SV2001000338A (es) 2001-11-30
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (es) 2003-06-30
AP2002002643A0 (en) 2002-12-31
AR034119A1 (es) 2004-02-04
CO5280200A1 (es) 2003-05-30
MXPA02008535A (es) 2002-12-13
KR20020075805A (ko) 2002-10-05
ZA200207110B (en) 2003-12-04
JP2003528101A (ja) 2003-09-24
IL151480A0 (en) 2003-04-10
IS6524A (is) 2002-08-23
TNSN01036A1 (en) 2005-11-10
YU66502A (sh) 2005-09-19
HUP0300136A2 (en) 2003-05-28
PL358271A1 (en) 2004-08-09
NO20024235D0 (no) 2002-09-05
CR6736A (es) 2004-03-10

Similar Documents

Publication Publication Date Title
EE200200506A (et) 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
EE200200405A (et) Pürido[2,3-d]pürimidiin-2,7-diamiinid kui kinaasiinhibiitorid
NO20021820D0 (no) Tyrosinkinaseinhibitorer
EP1161433A4 (en) TYROSINE KINASE INHIBITORS
AP2003002781A0 (en) Quinolinone derivatives as tyrosine kinase inhibitors
ATE257157T1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen als protein kinasen hemmer
PL373300A1 (en) Novel tyrosine kinase inhibitors
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
EP1259236A4 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
DE50103649D1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
DK1226136T3 (da) Tyrosinkinaseinhibitor
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002327342A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors
AU2002326760A1 (en) Tyrosine kinase inhibitors
AU2002326758A1 (en) Tyrosine kinase inhibitors